Aerie Pharmaceuticals Inc (AERI)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

4301 EMPEROR BOULEVARD DURHAM, NC 27703

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

Data as of 2021-07-19 09:14:59 -0400
Market Cap716.061 Million Shares Outstanding46.893 Million Avg 30-day Volume557.617 Thousand
P/E Ratio-4.07001 Dividend Yield EPS-3.83
Price/Sales8.35 Debt to Equity-34.99 EBITDA-132.287 Million
Price to Book Value-69.06 Forward PE1.94 Enterprise Value723.945 Million
Total Cash208.204 Million Current Debt93.364 Million Gross Profit59.826 Million
BETA0.60044 52-week High/Low21.3 / 9.01 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -17.9025
Data provided by IEX Cloud
View SEC Filings from AERI instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 156 149 4.7% 51 (2.99%) 48 (2.79%) 6.25%
13F shares: 46.301 Million 44.512 Million 4.02% 18.824 Million 16.565 Million 13.64%
% Ownership 98.6875 95.0805 3.79% 40.1212 35.3837 13.39%
New Positions: 27 22 22.73% 13 12 8.33%
Increased Positions 43 56 -23.21% 15 16 -6.25%
Closed Positions 19 20 -5.0% 10 9 11.11%
Reduced Positions 62 45 37.78% 19 17 11.76%
Total Calls 163.559 Thousand 111.833 Thousand 46.25% 158.7 Thousand 76 Thousand 108.82%
Total Puts 280.211 Thousand 10.674 Thousand 2525.17% 280 Thousand 10.6 Thousand 2541.51%
PUT/CALL Ratio 1.71 0.1 1610.0% 1.76 0.14 1157.14%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AERI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AERI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCGRAW BENJAMIN F III

  • Director
19,350 2021-06-17 1

CAGLE GERALD D.

  • Director
27,850 2021-06-17 1

GRYSKA DAVID W

  • Director
15,046 2021-06-17 1

CROARKIN RICHARD

  • Director
17,650 2021-06-17 1

DU TOIT MICHAEL

  • Director
17,650 2021-06-17 1

MCHUGH JULIE

  • Director
17,650 2021-06-17 1

MCDONNELL PETER J

  • Director
9,550 2021-06-17 1

ANIDO VICENTE JR CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
243,896 2021-02-23 3

KOPCZYNSKI CASEY C. CHIEF SCIENTIFIC OFFICER

  • Officer
264,469 2021-02-23 5

MITRO THOMAS A PRESIDENT AND COO

  • Officer
86,709 2021-02-23 3

RUBINO RICHARD J CHIEF FINANCIAL OFFICER

  • Officer
353,937 2021-02-23 3

LAROCCA JOHN GENERAL COUNSEL

  • Officer
40,437 2021-02-19 4

HOLLANDER DAVID CHIEF R&D OFFICER

  • Officer
33,838 2021-02-04 2

GOLDBERG MURRAY A

  • Director
36,050 2020-05-18 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL FUND III, L.P.

FORESITE CAPITAL FUND IV, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL MANAGEMENT IV, LLC

TANANBAUM JAMES B.

  • 10% Owner
No longer subject to file 2020-02-27 0

FORESITE CAPITAL MANAGEMENT IV, LLC

FORESITE CAPITAL FUND IV, L.P.

TANANBAUM JAMES B.

  • 10% Owner
5,524,591 2019-12-20 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
5,853,502 2018-07-23 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
3,643,191 2017-05-26 0

DUYK GEOFFREY M

  • Director
3,400 2017-02-14 0

MEHRA ANAND

  • Director
469,591 2015-04-14 0

LEVY BRIAN CHIEF MEDICAL OFFICER

  • Officer
16,313 2015-02-25 0

CLARUS LIFESCIENCES II, L.P.

CLARUS VENTURES II GP, L.P.

CLARUS VENTURES II, LLC

GALAKATOS NICHOLAS

HENNER DENNIS

LIPTAK ROBERT

SIMON NICHOLAS

STEINMETZ MICHAEL

WHEELER KURT

  • Director
  • 10% Owner
0 2015-01-28 0

TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

BONDERMAN DAVID

COULTER JAMES G

  • FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)
No longer subject to file 2014-11-25 0

ACP IV, L.P.

JANNEY DANIEL

NOHRA GUY P

ACMP IV LLC

  • 10% Owner
No longer subject to file 2014-07-16 0

SOFINNOVA VENTURE PARTNERS VII L P

SOFINNOVA MANAGEMENT VII, L.L.C.

HEALY JAMES

BUATOIS ERIC

POWELL MICHAEL

  • 10% Owner
No longer subject to file 2014-07-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CROARKIN RICHARD - Director

2021-06-21 16:11:21 -0400 2021-06-17 A 1,750 a 9,850 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

MCGRAW BENJAMIN F III - Director

2021-06-21 16:36:26 -0400 2021-06-17 A 7,800 a 7,800 direct

DU TOIT MICHAEL - Director

2021-06-21 16:18:45 -0400 2021-06-17 A 1,750 a 9,850 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

MCDONNELL PETER J - Director

2021-06-21 16:13:15 -0400 2021-06-17 A 7,800 a 7,800 direct

CAGLE GERALD D. - Director

2021-06-21 16:15:56 -0400 2021-06-17 A 1,750 a 20,050 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

GRYSKA DAVID W - Director

2021-06-21 16:39:05 -0400 2021-06-17 A 7,800 a 7,800 direct

MCGRAW BENJAMIN F III - Director

2021-06-21 16:36:26 -0400 2021-06-17 A 1,750 a 11,550 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

MCHUGH JULIE - Director

2021-06-21 16:21:03 -0400 2021-06-17 A 7,800 a 7,800 direct

MCDONNELL PETER J - Director

2021-06-21 16:13:15 -0400 2021-06-17 A 1,750 a 1,750 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

CROARKIN RICHARD - Director

2021-06-21 16:11:21 -0400 2021-06-17 A 7,800 a 7,800 direct

GRYSKA DAVID W - Director

2021-06-21 16:39:05 -0400 2021-06-17 A 1,750 a 5,250 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

DU TOIT MICHAEL - Director

2021-06-21 16:18:45 -0400 2021-06-17 A 7,800 a 7,800 direct

MCHUGH JULIE - Director

2021-06-21 16:21:03 -0400 2021-06-17 A 1,750 a 9,850 direct -1.2422 -8.3569 6.3806 3 -8.3569 6

CAGLE GERALD D. - Director

2021-06-21 16:15:56 -0400 2021-06-17 A 7,800 a 7,800 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AERIE PHARMACEUTICALS INC AERI 2021-07-23 22:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 21:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 21:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 20:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 20:15:05 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 19:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 19:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 18:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 18:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 17:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 17:15:02 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 16:45:02 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 16:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 15:45:02 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 15:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 14:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 14:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 13:45:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 13:15:03 UTC -0.3381 0.4181 650000
AERIE PHARMACEUTICALS INC AERI 2021-07-23 12:45:03 UTC -0.3381 0.4181 650000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund AERI -40.0 shares, $-540.0 2020-03-31 N-PORT
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund AERI -112.0 shares, $-2152.64 2019-09-30 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund AERI -22577.0 shares, $-415191.03 2021-02-26 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund AERI -1300.0 shares, $-23231.0 2021-03-31 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio AERI -5682.0 shares, $-101537.34 2021-03-31 N-PORT
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio AERI -25900.0 shares, $-462833.0 2021-03-31 N-PORT
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio AERI -5300.0 shares, $-94711.0 2021-03-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund AERI -29001.0 shares, $-518247.87 2021-03-31 N-PORT

Short Position History (International Only)

Holder Net Short Position Position Date Origin
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.69% 2016-01-11 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.59% 2016-02-18 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.8% 2015-10-26 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.7% 2015-10-21 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.51% 2015-10-16 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.79% 2015-12-07 GERMANY

Elevate your investments